Skip to main content

What are you looking for?

Write the name, title or any keyword related to what you are looking for and select which content category it belongs to.

The RENAL LIFECYCLE trial; A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease

  • Protocol code: 202100617
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Soler Romeo, Maria Jose
  • Research group:  Nefrologia i trasplantament renal
  • Service: Nefrologia
  • Phase: Fase III
  • Recruiting: Closed
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Impact of Albumin on Renal function in critically ill patients with Septic Shock and a high risk of Acute Kidney Injury. A Randomized Controlled Trial

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad del remibrutinib en pacientes con miastenia grave generalizada, seguido de una fase de extensión abierta.

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A phase IIa double-blind, randomized, parallel-arm, placebo-controlled trial to investigate the effects of three dose levels of CIT-013 on disease activity in patients with moderately active rheumatoid arthritis.

  • Protocol code: CITRYLL002-Citydream
  • EudraCT code: 2024-517356-35
  • Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified
  • Principal investigator:  Lopez Lasanta, Maria America
  • Research group:  Reumatologia
  • Service: Reumatologia
  • Phase: Phase II
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Year
2025
Títol Complet
Servei per l'organització i execució tècnica de la Cursa Vall d'Hebron a càrrec de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
ORGANITZACIÓ CURSA
Codi
24987842
Data publicació
Year
2025
Títol Complet
Servei d'assessorament legal en l'àmbit laboral, destinat a la Unitat de Recursos Humans de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
ASSE. LEGAL LABORAL EXTERN
Codi
24987843
Data publicació
Year
2025
Títol Complet
Servicio de creación y desarrollo de cursos online en el ámbito de ciencias de la salud a cargo del Proyecto 101060102 "GIMM-CARE: boosting clinical research for the benefit of society", destinado al Grupo de Estrategia Externa de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
CREACIÓN Y DESARROLLO CURSOS ONLINE CIENCIAS SALUD
Codi
24987844
Data publicació

Professionals

Olga Gabaldà Moran

Sóc infermera amb molta experiència quirúrgica. actualment desenvolupo tasques d'infermera gestora com a supervisora d'infermeria del bloc quirúrgic.

Professionals

Marta Dalmau Artal

Professionals

Imma Garcia Ruiz

Year
2025
Títol Complet
Servei de gestió del crèdit FUNDAE de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR) derivat de els accions formatives que contenen els plans de formació anuals.
Expedient
GESTIÓ CRÈDIT FUNDAE
Codi
24987728
Data publicació

Estudio en fase III, aleatorizado, doble ciego, controlado con placebo de Talazoparib con Enzalutamida en el cáncer de próstata metastásico resistente a la castración.

  • Protocol code: C3441021
  • EudraCT code: 2017-003295-31
  • Pathology: Tumors
  • Principal investigator:  Valderrama Rodríguez, Angelica
  • Service: Sense classificar
  • Phase: Phase III
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

ESTUDIO DE FASE III, ALEATORIZADO, DOBLE CIEGO DE TALAZOPARIB CON ENZALUTAMIDA FRENTE A PLACEBO CON ENZALUTAMIDA EN HOMBRES CON CÁNCER DE PRÓSTATA METASTÁSICO SENSIBLE A LA CASTRACIÓN Y CON MUTACIONES EN GENES DE REPARACIÓN DEL DAÑO EN EL ADN (TALAPRO-3)

  • Protocol code: C3441052
  • EudraCT code: 2021-000248-23
  • Principal investigator:  Valderrama Rodríguez, Angelica
  • Service: Unclassified
  • Phase: Phase III
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio en fase I, por primera vez en seres humanos, sobre la seguridad, la farmacocinética y la eficacia preliminar de AMX-500 en participantes con cáncer de próstata resistente a la castración metastásico (CPRCm)

  • Protocol code: AMX-500-001
  • EudraCT code: No aplica
  • Pathology: Tumors
  • Principal investigator:  Valderrama Rodríguez, Angelica
  • Service: Unclassified
  • Phase: Fase I
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo Fase I, abierto, aleatorizado, multicéntrico para investigar los efectos biológicos de AZD5305 en monoterapia, Darolutamida en monoterapia, y ambos en combinación administrados antes de la prostatectomía radical en hombres con cáncer de próstata recién diagnosticado

  • Protocol code: D9721C00002
  • EudraCT code: No aplica
  • Pathology: Tumors
  • Principal investigator:  Valderrama Rodríguez, Angelica
  • Service: Unclassified
  • Phase: Phase I
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase 1 de MOMA-313 administrado como monoterapia o en combinación con un inhibidor de la PARP en participantes con tumores sólidos avanzados o metastásicos.

  • Protocol code: MOMA-313-001
  • EudraCT code: No aplica
  • Pathology: Tumors
  • Principal investigator:  Valderrama Rodríguez, Angelica
  • Service: Unclassified
  • Phase: Phase I
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Ensayo fase III, aleatorizado, de 2 cohortes, soble ciego, controlado con placebo de AZD5305 en combinación con un nuevo agente hormonal a elección del investigador en pacientes con cáncer de próstata metastásico hormonosensible con y sin mutación en los genes de reparación por recombinación homóloga (HRR) (EvoPar-Prostate01).

  • Protocol code: D9723C00001
  • EudraCT code: No aplica
  • Pathology: Tumors
  • Principal investigator:  Valderrama Rodríguez, Angelica
  • Service: Unclassified
  • Phase: Phase III
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.